Page last updated: 2024-11-06

jacaranone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Jacaranone is a natural product with potent anti-inflammatory and antioxidant properties. It has been isolated from the bark of the Jacaranda mimosifolia tree, a flowering plant native to South America. Jacaranone's anti-inflammatory activity has been attributed to its ability to inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. Furthermore, jacaranone has shown promising results in preclinical studies as a potential treatment for neurodegenerative diseases like Alzheimer's disease. Its antioxidant properties have been linked to its ability to scavenge free radicals and protect cells from oxidative damage. Research on jacaranone continues to explore its therapeutic potential and its underlying mechanisms of action.'

jacaranone: sedative; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73307
CHEMBL ID469293
SCHEMBL ID19624651
MeSH IDM0060549

Synonyms (23)

Synonym
NSC251682 ,
60263-07-2
jacaranone
2,5-cyclohexadiene-1-acetic acid, 1-hydroxy-4-oxo-, methyl ester
methyl 2-(1-hydroxy-4-oxo-cyclohexa-2,5-dien-1-yl)acetate
nsc-251682
jacaramome
NCI60_002013
nsc289076
nsc-289076
inchi=1/c9h10o4/c1-13-8(11)6-9(12)4-2-7(10)3-5-9/h2-5,12h,6h2,1h3
wjzsknrprwcllk-uhfffaoysa-
methyl 2-(1-hydroxy-4-oxocyclohexa-2,5-dien-1-yl)acetate
CHEMBL469293
nsc 289076
1-hydroxy-4-oxo-2,5-cyclohexadiene-1-acetic acid methyl ester
bdbm50480311
SCHEMBL19624651
?jacaranone
methyl (1-hydroxy-4-oxo-2,5-cyclohexandienyl)acetate
methyl (1-hydroxy-4-oxocyclohexa-2,5-dien-1-yl)acetate
DTXSID70975675
AKOS040762944

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID399848In vivo cytotoxicity against mouse P388 cells at 2 mg/kg relative to control
AID357845Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method
AID477926Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Jacaranone-derived glucosidic esters from Jacaranda glabra and their activity against Plasmodium falciparum.
AID397122Inhibition of HIV1 RT
AID477925Antiplasmodial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3]H-hypoxanthine incorporation assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Jacaranone-derived glucosidic esters from Jacaranda glabra and their activity against Plasmodium falciparum.
AID399849Cytotoxicity against human KB cells
AID399846In vivo cytotoxicity against mouse P388 cells
AID399845Cytotoxicity against human KB cells
AID357846Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (46.67)29.6817
2010's8 (53.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]